• Record: found
  • Abstract: found
  • Article: not found

Safety and efficacy of MRI-based thrombolysis in unclear-onset stroke. A preliminary report.

Cerebrovascular Diseases (Basel, Switzerland)

therapeutic use, Urokinase-Type Plasminogen Activator, Treatment Outcome, Tissue Plasminogen Activator, standards, Thrombolytic Therapy, therapy, Stroke, Risk Assessment, Retrospective Studies, Middle Aged, Male, Magnetic Resonance Angiography, diagnosis, Intracranial Hemorrhages, Humans, Female, Diffusion Magnetic Resonance Imaging, Aged

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Standard selection criteria for thrombolysis typically exclude patients with acute ischemic stroke with unclear onset. Multimodal MRI screening may be able to identify those with a favorable benefit-risk ratio for thrombolysis. We aimed to evaluate the safety and efficacy of MRI-based thrombolysis in unclear-onset stroke (UnCLOS). We reviewed the thrombolysis database registries from 3 medical centers in Korea. Subjects received thrombolysis with intravenous tissue plasminogen activator (tPA) or combined intravenous tPA and intra-arterial urokinase within 3 h, or intra-arterial urokinase within 6 h from symptom detection. For patients with UnCLOS, MRI-specific eligibility criteria (i.e. positive perfusion-diffusion mismatch and absence of well-developed fluid-attenuated inversion recovery changes of acute diffusion lesions) were applied. Rates of immediate and 5-day recanalization, early neurological improvement and symptomatic intracranial hemorrhage (ICH) within 48 h after treatment and 3-month modified Rankin Scale (mRS) scores were compared between patients with UnCLOS and those with clear-onset stroke (CLOS). 32 patients with UnCLOS and 223 patients with CLOS were included. Baseline characteristics were comparable between the two groups, except that the proportion of MRI screening was higher, and detection-to-door time and door-to-needle time were longer in the UnCLOS group (p < 0.01). Rates of recanalization (immediate, 81.3 vs. 63.1%; delayed, 80.6 vs. 69.1%), early neurological improvement (on day 1, 46.9 vs. 35.9%; on day 7, 50.0 vs. 49.3%), symptomatic ICH (6.3 vs. 5.8%) and 3-month outcome (mRS 0-1, 37.5 vs. 35.0%; mRS 0-2, 50.0 vs. 49.3%) did not differ between the UnCLOS and CLOS groups. These preliminary results suggest that thrombolysis based on MRI criteria may safely be applied to acute stroke patients with unclear onset. 2008 S. Karger AG, Basel.

      Related collections

      Author and article information



      Comment on this article